Please view our career page for future employment with Venenum Biodesign.
View Job Postings
News and Events
Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services
Genesis Biotechnology Group announces second year of CRO relationship with Yale University
Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services
Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima.
Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development (GD3).
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma.
Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.
Genesis Biotechnology Group announces partnership with Yale University
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima
Dr. Ilana Stroke to present at the Society for Laboratory Automation and Screening (SLAS) 2015 in Washington, D.C.
Dr. Michael S. McQueney is on the Organizing Committee of the 18th International Conference of the Inflammation Research Association, 2014, and is co-chairing a session on Immunity and Inflammation in Cancer. Dr. McQueney is on the Board of Directors of the Inflammation Research Association.
Dr. James Beasley, Dr. Ilana Stroke, and Dr. Robert Swanson to present at 2013 SLAS in Orlando, Florida.
Dr. James Beasley to present at 2012 SLAS in Orlando, Florida.
VENENUM Biodesign exhibits at 2012 SLAS in San Diego.
VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs Hamilton, NJ. June 22, 2011.
VENENUM Biodesign: Biotech Company Relocates to State of the Art Facility
Hamilton, NJ. Jan. 3, 2011
Biotech Company Releases New Web Presence
Hamilton, NJ. Dec. 21, 2010